Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW.

J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732.

2.

A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW.

Life Sci. 2010 Apr 24;86(17-18):646-53. doi: 10.1016/j.lfs.2010.02.014. Epub 2010 Feb 20.

3.

Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid.

Gu X, Mei F, Liu Y, Zhang R, Zhang J, Ma Z.

Anesth Analg. 2011 Aug;113(2):405-11. doi: 10.1213/ANE.0b013e31821d1062. Epub 2011 Apr 25.

PMID:
21519057
4.

Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.

Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A.

Br J Pharmacol. 2010 Jun;160(3):561-73. doi: 10.1111/j.1476-5381.2009.00629.x. Epub 2010 Mar 3.

5.

Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.

Tambaro S, Casu MA, Mastinu A, Lazzari P.

Eur J Pharmacol. 2014 Apr 15;729:67-74. doi: 10.1016/j.ejphar.2014.02.013. Epub 2014 Feb 20.

PMID:
24561047
6.

Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.

Biol Psychiatry. 2015 Mar 1;77(5):475-87. doi: 10.1016/j.biopsych.2014.04.009. Epub 2014 Apr 25.

7.

Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M.

Anesth Analg. 2010 Jul;111(1):99-109. doi: 10.1213/ANE.0b013e3181e0cdaf. Epub 2010 Jun 3.

8.

The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.

Kinsey SG, Mahadevan A, Zhao B, Sun H, Naidu PS, Razdan RK, Selley DE, Imad Damaj M, Lichtman AH.

Neuropharmacology. 2011 Feb-Mar;60(2-3):244-51. doi: 10.1016/j.neuropharm.2010.09.004. Epub 2010 Sep 16.

9.

Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.

Curto-Reyes V, Boto T, Hidalgo A, Menéndez L, Baamonde A.

Eur J Pharmacol. 2011 Oct 1;668(1-2):184-9. doi: 10.1016/j.ejphar.2011.06.057. Epub 2011 Jul 13.

PMID:
21771590
10.

Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.

Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer MD.

Br J Pharmacol. 2011 Jan;162(2):428-40. doi: 10.1111/j.1476-5381.2010.01046.x.

11.

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.

Anand P, Whiteside G, Fowler CJ, Hohmann AG.

Brain Res Rev. 2009 Apr;60(1):255-66. doi: 10.1016/j.brainresrev.2008.12.003. Epub 2008 Dec 25. Review.

12.

Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.

Cui JH, Kim WM, Lee HG, Kim YO, Kim CM, Yoon MH.

Neurosci Lett. 2011 Apr 15;493(3):67-71. doi: 10.1016/j.neulet.2010.12.052. Epub 2010 Dec 31.

PMID:
21195743
13.

Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.

Davis MP.

Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16. Review.

PMID:
24836296
14.

The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.

Klauke AL, Racz I, Pradier B, Markert A, Zimmer AM, Gertsch J, Zimmer A.

Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20. doi: 10.1016/j.euroneuro.2013.10.008. Epub 2013 Oct 22.

15.

Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors.

Scutt A, Williamson EM.

Calcif Tissue Int. 2007 Jan;80(1):50-9. Epub 2007 Jan 4.

PMID:
17205329
16.

Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Fu W, Taylor BK.

Neurosci Lett. 2015 May 19;595:1-6. doi: 10.1016/j.neulet.2015.04.002. Epub 2015 Apr 3.

17.

Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.

Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK.

PLoS One. 2011;6(9):e23901. doi: 10.1371/journal.pone.0023901. Epub 2011 Sep 7.

18.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

19.

Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.

Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, Strassle BW, Cummons TA, Piesla MJ, Harrison JE, Whiteside GT, Kennedy JD.

Br J Pharmacol. 2007 Aug;151(7):1061-70. Epub 2007 Jun 4. Erratum in: Br J Pharmacol. 2007 Aug;151(7):1137.

20.

Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.

Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH, Idris AI.

J Biol Chem. 2015 Sep 4;290(36):22049-60. doi: 10.1074/jbc.M115.649608. Epub 2015 Jul 20.

Supplemental Content

Support Center